D. Western Therapeutics Institute, Inc. Reports Consolidated Financial Results for the First Quarter Ended March 31, 2021
May 13, 2021
Share
D. Western Therapeutics Institute, Inc. reported consolidated financial results for the first quarter ended March 31, 2021. For the period, the company reported net sales of JPY 89 million compared to JPY 74 million a year ago. Operating loss was JPY 50 million compared to JPY 50 million a year ago. Loss was JPY 41.343 million compared to JPY 53.034 million a year ago. Loss per share was JPY 1.41 compared to JPY 1.66 a year ago.
D.Western Therapeutics Institute, Inc. is a Japan-based company engaged in the research and development of new pharmaceuticals. The Company generates revenue from licensing of its developed drugs to other companies. As of December 31, 2012, the Companyâs drug pipeline included anti-thrombotic medicine K-134, therapeutic agent K-115 for glaucoma, and anticancer drug HMN-214. Its newly-developed products include new anti-thrombotic medicine and signal-transduction inhibitors, including therapeutic agent for high-blood pressure, protective agent for nerves, therapeutic agent for atherosclerosis, ophthalmologic drug and anticancer drug, among others. The Company is also developing new drug candidate compounds focusing on protein kinase inhibitors and involving in ophthalmic surgical adjuvant business, which includes ingredient of Brilliant Blue G-250.
D. WESTERN THERAPEUTICS INSTITUTE, INC. 